1st Counsel – Lifestyle
Author:
C4 Therapeutics, Inc.
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 9, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 9, 2026